Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Abbisko was a clinical-stage biopharmaceutical company in China. The company plans to raise up to USD 300m via  a Hong Kong listing.The company's product pipeline has a strong focus on selective FGFR small molecules for oncology therapy. Its core products ABSK011 is an FGFR4 inhibitor and ABSK091 is a pan-FGFR inhibitor, which was in-licensed from AstraZeneca with global rights. We think its products have yet to show convincing clinical numbers despite a strong prospect from pre-clinical readings. We think the company's management team is experienced with proven track record of product development and commercialization. The investor line-up is strong.

Abbisko was a clinical-stage biopharmaceutical company in China. The company plans to raise up to USD 300m via  a Hong Kong listing.The company's product pipeline has a strong focus on selective FGFR small molecules for oncology therapy. Its core products ABSK011 is an FGFR4 inhibitor and ABSK091 is a pan-FGFR inhibitor, which was in-licensed from AstraZeneca with global rights. We think its products have yet to show convincing clinical numbers despite a strong prospect from pre-clinical readings. We think the company's management team is experienced with proven track record of product development and commercialization. The investor line-up is strong.

Abbisko (和誉) Pre-IPO: Strong Team but FGFR Inhibitors Not Convincing Yet

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Recently, <a href="https://www.smartkarma.com/entities/innocare-pharma-ltd" target="_blank" data-smartkarma-citation="entities:28355:1" rel="noopener">InnoCare Pharma Ltd (9969 HK)</a> released 2021/1H financial results. The revenue was RMB102 million, up 13490.51% YoY, which was mainly due to the sales growth of orelabrutinib. Net loss was narrowed from RMB337 in 2020/1H to RMB213 million in 2021/1H, indicating improvement. Meanwhile, InnoCare is also going to be listed on the SSE STAR market, which is expected to be another biopharmaceutical company with "A+H" shares listing. This insight mainly analyzed the core product, pipeline and the concerns of the Company.

Recently, InnoCare Pharma Ltd (9969 HK) released 2021/1H financial results. The revenue was RMB102 million, up 13490.51% YoY, which was mainly due to the sales growth of orelabrutinib. Net loss was narrowed from RMB337 in 2020/1H to RMB213 million in 2021/1H, indicating improvement. Meanwhile, InnoCare is also going to be listed on the SSE STAR market, which is expected to be another biopharmaceutical company with "A+H" shares listing. This insight mainly analyzed the core product, pipeline and the concerns of the Company.

InnoCare Pharma Ltd (9969.HK) - Risk of Becoming Mediocre

On June 16, <a href="https://www.smartkarma.com/entities/abbisko-cayman-limited" target="_blank" data-smartkarma-citation="entities:33511:1" rel="noopener">Abbisko Cayman (ABB HK)</a> submitted a prospectus to the HKEX to be listed on the main board. Abbisko is a R&amp;D-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies, with a pipeline of 14 programs focused on oncology. This insight mainly analyzed the four important product candidates at the clinical stage (ABSK011, ABSK091, ABSK021 and ABSK081) in the pipeline.

On June 16, Abbisko Cayman (ABB HK) submitted a prospectus to the HKEX to be listed on the main board. Abbisko is a R&amp;D-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies, with a pipeline of 14 programs focused on oncology. This insight mainly analyzed the four important product candidates at the clinical stage (ABSK011, ABSK091, ABSK021 and ABSK081) in the pipeline.

Pre-IPO Abbisko Cayman - It Still Takes Some Time for Commercialization

China

Abbisko Cayman Limited operates as a biopharmaceutical company. The Company dedicated to the discovery and development of innovative and differentiated small molecule incology therapies. Abbisko Cayman provides services in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbisko Cayman (2256 HK)

Abbisko (和誉) Pre-IPO: Strong Team but FGFR Inhibitors Not Convincing Yet

We look at the two main FGFR inhibitor products of Abbisko which is looking to raise up to USD 300m via a Hong Kong listing.

Ke Yan, CFA, FRM

InnoCare Pharma Ltd (9969.HK) - Risk of Becoming Mediocre

This article analyzed InnoCare in terms of its core product orelabrutinib, key product candidates in the pipeline, the competitive landscape, the...

Xinyao (Criss) Wang

Pre-IPO Abbisko Cayman - It Still Takes Some Time for Commercialization

This article analyzed Abbisko in terms of its four product candidates at the clinical stage (ABSK011, ABSK091, ABSK021 and ABSK081) in the...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)